Neuroelectrics Barcelona S.L.U.

Neuroelectrics develops a cloud-based, personalized neuromodulation platform (Starstim) for treating brain disorders including refractory focal epilepsy and treatment-resistant depression. The platform integrates three modular components: a multi-channel transcranial electrical stimulation (tES) headpiece for EEG monitoring and neuromodulation, cloud-based secure remote treatment delivery, and AI-driven personalization based on computational neuroscience, data science, and patient physiological data. The company's approach targets dysfunctional neural circuits holistically rather than single brain nodes, offering a non-invasive, non-drug therapeutic option for patients unresponsive to pharmacological or surgical interventions. Starstim hardware and research tools are widely used in neuroscience research, with hundreds of published papers utilizing the platform. The company is conducting pivotal clinical trials in refractory focal epilepsy (NCT04770337) and pilot studies in at-home depression treatment (NCT05205915). Neuroelectrics serves both clinical therapeutic and research markets, with regulatory clearance for investigational use in multiple jurisdictions.